129 related articles for article (PubMed ID: 31705700)
1. Hemi-ablative low-dose-rate prostate brachytherapy for unilateral localised prostate cancer.
Langley S; Uribe J; Uribe-Lewis S; Franklin A; Perna C; Horton A; Cunningham M; Higgins D; Deering C; Khaksar S; Laing R
BJU Int; 2020 Mar; 125(3):383-390. PubMed ID: 31705700
[TBL] [Abstract][Full Text] [Related]
2. Is hemi-gland focal LDR brachytherapy as effective as whole-gland treatment for unilateral prostate cancer?
Langley S; Uribe J; Uribe-Lewis S; Mehta S; Mikropoulos C; Perna C; Otter S; Horton A; Cunningham M; Higgins D; Langley S; Deering C; Khaksar S
Brachytherapy; 2022; 21(6):870-876. PubMed ID: 36207244
[TBL] [Abstract][Full Text] [Related]
3. Hemi-gland focal low dose rate prostate brachytherapy: An analysis of dosimetric outcomes.
Laing R; Franklin A; Uribe J; Horton A; Uribe-Lewis S; Langley S
Radiother Oncol; 2016 Nov; 121(2):310-315. PubMed ID: 27814981
[TBL] [Abstract][Full Text] [Related]
4. Dosimetry Modeling for Focal Low-Dose-Rate Prostate Brachytherapy.
Al-Qaisieh B; Mason J; Bownes P; Henry A; Dickinson L; Ahmed HU; Emberton M; Langley S
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):787-93. PubMed ID: 25936808
[TBL] [Abstract][Full Text] [Related]
5. Dosimetry modeling for focal high-dose-rate prostate brachytherapy.
Mason J; Al-Qaisieh B; Bownes P; Thwaites D; Henry A
Brachytherapy; 2014; 13(6):611-7. PubMed ID: 25085456
[TBL] [Abstract][Full Text] [Related]
6. Focal high-dose-rate brachytherapy: a dosimetric comparison of hemigland vs. conventional whole-gland treatment.
Kamrava M; Chung MP; Kayode O; Wang J; Marks L; Kupelian P; Steinberg M; Park SJ; Demanes DJ
Brachytherapy; 2013; 12(5):434-41. PubMed ID: 23406987
[TBL] [Abstract][Full Text] [Related]
7. Comparative Analysis of Clinical Outcomes and Procedural Costs between the Conventional Two-stage Technique and 4D Brachytherapy for Early Prostate Cancer.
Langley SEM; Uribe J; Uribe-Lewis S; Money-Kyrle J; Perna C; Khaksar S; Soares R; Laing R
Clin Oncol (R Coll Radiol); 2018 Jan; 30(1):57-64. PubMed ID: 29054374
[TBL] [Abstract][Full Text] [Related]
8. The results of real-time brachytherapy for the management of low- and intermediate-risk prostate cancer in patients with prostate volumes up to 100 mL.
Dallas NL; Malone PR; Jones A; Doggart AJ; McConway KJ; Rogers PB
BJU Int; 2012 Aug; 110(3):383-90. PubMed ID: 22332791
[TBL] [Abstract][Full Text] [Related]
9. Long-term oncological outcomes and toxicity in 597 men aged ≤60 years at time of low-dose-rate brachytherapy for localised prostate cancer.
Langley SEM; Soares R; Uribe J; Uribe-Lewis S; Money-Kyrle J; Perna C; Khaksar S; Laing R
BJU Int; 2018 Jan; 121(1):38-45. PubMed ID: 28670842
[TBL] [Abstract][Full Text] [Related]
10. Medium-term oncological and functional outcomes of hemi-gland brachytherapy using iodine-125 seeds for intermediate-risk unilateral prostate cancer.
Saito K; Matsuoka Y; Toda K; Yoshida S; Yokoyama M; Yoshimura R; Kihara K; Fujii Y
Brachytherapy; 2021; 20(4):842-848. PubMed ID: 33883093
[TBL] [Abstract][Full Text] [Related]
11. From whole gland to hemigland to ultra-focal high-dose-rate prostate brachytherapy: A dosimetric analysis.
Banerjee R; Park SJ; Anderson E; Demanes DJ; Wang J; Kamrava M
Brachytherapy; 2015; 14(3):366-72. PubMed ID: 25680768
[TBL] [Abstract][Full Text] [Related]
12. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
13. The impact of hormone therapy on post-implant dosimetry and outcome following Iodine-125 implant monotherapy for localised prostate cancer.
Ash D; Al-Qaisieh B; Bottomley D; Carey B; Joseph J
Radiother Oncol; 2005 Jun; 75(3):303-6. PubMed ID: 15890423
[TBL] [Abstract][Full Text] [Related]
14. Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time.
Kollmeier MA; McBride S; Taggar A; Anderson E; Lin M; Pei X; Weiji S; Voros L; Cohen G; Yamada Y; Zelefsky MJ
Brachytherapy; 2017; 16(6):1091-1098. PubMed ID: 28838648
[TBL] [Abstract][Full Text] [Related]
15. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
[TBL] [Abstract][Full Text] [Related]
16. Iodine-125 brachytherapy for localized prostate cancer and urinary morbidity: a prospective comparison of two seed implant methods-preplanning and intraoperative planning.
Matzkin H; Kaver I; Stenger A; Agai R; Esna N; Chen J
Urology; 2003 Sep; 62(3):497-502. PubMed ID: 12946754
[TBL] [Abstract][Full Text] [Related]
17. Report on the early efficacy and tolerability of I(125) permanent prostate brachytherapy from a UK multi-institutional database.
Mitchell DM; Mandall P; Bottomley D; Hoskin PJ; Logue JP; Ash D; Ostler P; Elliott T; Henry A; Wylie JP
Clin Oncol (R Coll Radiol); 2008 Dec; 20(10):738-44. PubMed ID: 18951769
[TBL] [Abstract][Full Text] [Related]
18. Toxicity and early biochemical outcomes from 125iodine prostate brachytherapy in the UK. A prospective study.
Henderson A; Ismail AK; Cunningham M; Aldridge S; Loverock L; Langley SE; Laing RW
Clin Oncol (R Coll Radiol); 2004 Apr; 16(2):95-104. PubMed ID: 15074730
[TBL] [Abstract][Full Text] [Related]
19. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
20. Impact of post-implant dosimetric parameters on the quality of life of patients treated with low-dose rate brachytherapy for localised prostate cancer: results of a single-institution study.
Veccia A; Caffo O; Fellin G; Mussari S; Ziglio F; Maines F; Tomio L; Galligioni E
Radiat Oncol; 2015 Jun; 10():130. PubMed ID: 26054532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
